上海药明生物技术有限公司 Wuxi Biologics Mediaroom

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

* Contributing to the United Nations Sustainable Development Goals, driving equitable access to h...

2026-04-29 20:30 3128

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract ...

2026-04-24 19:03 2424

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...

2026-04-23 14:14 2716

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

* Company is among the first in China's drug-device combination products sector to obtain this ce...

2026-04-15 10:39 2688

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-30 13:33 5702

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Co...

2026-03-25 18:22 5391

WuXi Biologics Reports Record 2025 Annual Results

* Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew ov...

2026-03-24 19:44 4275

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffir...

2026-03-22 09:30 3859

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2026-03-13 11:09 4506

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-03-02 11:21 6028

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Researc...

2026-02-03 11:22 9167

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-29 10:39 8900

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Researc...

2026-01-26 17:35 15710

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...

2026-01-15 12:00 7794

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 9676

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 6803

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-12 21:09 6867

Latest News

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year

WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture

WuXi Biologics Reports Record 2025 Annual Results

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index